AbbVie
ABBV
288.13
+5.45
+1.93%
AbbVie
US · ABBV
#30 by market cap
Listed 1970
288.13
+5.45
+1.93%
Live - 5344 symbols - heartbeat 32s ago
· 2026-10-20 11:00
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.89, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +8.57% YoY
Margins
- Gross margin
- 70.24%
- Operating margin
- 32.85%
- Net margin
- 6.84%
Key ratios & quality
- Enterprise valuei
- 571.39B
- Altman Z-Scorei
- 2.89
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 32.75B | 33.27B | 45.80B | 56.20B | 58.05B | 54.32B | 56.33B | 61.16B |
| Gross profit | 25.04B | 25.83B | 30.42B | 38.75B | 40.64B | 33.90B | 39.43B | 42.96B |
| Selling & admin expenses | 7.40B | 6.94B | 11.30B | 12.35B | 15.26B | 12.87B | 14.75B | 14.01B |
| Research & development | 10.75B | 6.79B | 7.76B | 8.05B | 6.51B | 7.68B | 12.79B | 9.10B |
| Operating profit | 6.38B | 12.98B | 11.36B | 17.92B | 18.81B | 13.54B | 11.89B | 20.09B |
| Pretax profit | 5.20B | 8.43B | 3.40B | 12.99B | 13.48B | 6.25B | 3.72B | 6.60B |
| Tax | -490.00M | 544.00M | -1.22B | 1.44B | 1.63B | 1.38B | -570.00M | 2.36B |
| Net profit | 5.69B | 7.88B | 4.62B | 11.55B | 11.85B | 4.87B | 4.29B | 4.23B |
| Basic EPS | 4 | 5 | 3 | 6 | 7 | 3 | 2 | 2 |
| Diluted EPS | 3.66 | 5.28 | 2.72 | 6.45 | 6.63 | 2.72 | 2.39 | 2.37 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 13.34B | 15.42B | 15.78B | 16.62B | 15.00B | 16.99B |
| Gross profit | 9.34B | 11.08B | 10.47B | 12.07B | 10.78B | 12.70B |
| Selling & admin expenses | 3.29B | 3.25B | 3.57B | 3.90B | 3.58B | 3.63B |
| Research & development | 2.07B | 2.13B | 2.32B | 2.58B | 2.47B | 2.34B |
| Operating profit | 3.98B | 5.72B | 4.58B | 5.81B | 4.73B | 6.72B |
| Pretax profit | 1.66B | 1.55B | 714.00M | 2.67B | 1.04B | 4.28B |
| Tax | 372.00M | 613.00M | 526.00M | 853.00M | 342.00M | 662.00M |
| Net profit | 1.29B | 941.00M | 188.00M | 1.82B | 697.00M | 3.62B |
| Basic EPS | 1 | 1 | 0 | 1 | 0 | 2 |
| Diluted EPS | 0.72 | 0.52 | 0.10 | 1.02 | 0.39 | 2.03 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 16.95B | 49.52B | 24.17B | 27.93B | 28.46B | 33.00B | 25.58B | 29.06B |
| Cash & ST investments | 8.06B | 39.92B | 8.48B | 9.83B | 9.23B | 12.82B | 5.56B | 5.26B |
| Inventory | 1.61B | 1.81B | 3.31B | 3.13B | 3.58B | 4.10B | 4.18B | 4.95B |
| Total assets | 59.35B | 89.12B | 150.57B | 146.53B | 138.81B | 134.71B | 135.16B | 133.96B |
| Total current liabilities | 17.24B | 15.59B | 28.66B | 35.19B | 29.54B | 37.84B | 38.75B | 43.29B |
| Short-term debt | 5.31B | 3.75B | 8.50B | 12.50B | 4.14B | 7.19B | 6.80B | 8.56B |
| Long-term debt | 35.00B | 62.98B | 77.55B | 64.19B | 59.14B | 52.19B | 60.34B | 58.94B |
| Total liabilities | 67,798,000,000.00 | 97,287,000,000.00 | 137,468,000,000.00 | 131,093,000,000.00 | 121,518,000,000.00 | 124,314,000,000.00 | 131,797,000,000.00 | 137,188,000,000.00 |
| Total equity | -8.45B | -8.17B | 13.10B | 15.44B | 17.29B | 10.40B | 3.36B | -3.23B |
| Retained earnings | 3.37B | 4.72B | 1.06B | 3.13B | 4.78B | -1.00B | -7.90B | -15.49B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 27.68B | 29.26B | 28.54B | 29.06B | 33.53B | 33.67B |
| Cash & ST investments | 5.18B | 6.47B | 5.67B | 5.26B | 9.39B | 6.57B |
| Inventory | 4.53B | 4.96B | 4.94B | 4.95B | 5.05B | 5.13B |
| Total assets | 136.17B | 137.18B | 133.90B | 133.96B | 136.46B | 135.12B |
| Total current liabilities | 36.40B | 39.77B | 39.39B | 43.29B | 42.10B | 41.64B |
| Short-term debt | 5.36B | 7.52B | 5.77B | 8.56B | 8.33B | 8.34B |
| Long-term debt | 64.53B | 62.96B | 62.97B | 58.94B | 64.53B | 62.48B |
| Total liabilities | 134,703,000,000.00 | 137,320,000,000.00 | 136,497,000,000.00 | 137,188,000,000.00 | 143,075,000,000.00 | 141,003,000,000.00 |
| Total equity | 1.46B | -138.00M | -2.60B | -3.23B | -6.61B | -5.89B |
| Retained earnings | -9.53B | -11.50B | -14.23B | -15.49B | -17.87B | -17.33B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 13.43B | 13.32B | 17.59B | 22.78B | 24.94B | 22.84B | 18.81B | 19.03B |
| Depreciation & amortization | 1.77B | 2.02B | 6.47B | 8.52B | 8.47B | 8.70B | 8.39B | 8.14B |
| Free cash flow | 12.79B | 12.77B | 16.79B | 21.99B | 24.25B | 22.06B | 17.83B | 17.82B |
| Dividends paid | -5.58B | -6.37B | -7.72B | -9.26B | -10.04B | -10.54B | -11.03B | -11.66B |
| Stock buybacks / issuance | -12.01B | -629.00M | -978.00M | -934.00M | -1.49B | -1.97B | -1.71B | -980.00M |
| Ending cash balance | 7.29B | 39.92B | 8.45B | 9.75B | 9.20B | 12.81B | 5.52B | 5.23B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 1.64B | 5.15B | 7.02B | 5.22B | 3.83B | 3.44B |
| Depreciation & amortization | 2.04B | 2.05B | 2.06B | 1.99B | 1.94B | 1.88B |
| Free cash flow | 1.40B | 4.88B | 6.64B | 4.89B | 3.56B | 3.11B |
| Dividends paid | -2.93B | -2.91B | -2.91B | -2.91B | -3.09B | -3.07B |
| Stock buybacks / issuance | -961.00M | -12.00M | -4.00M | -3.00M | -1.49B | -9.00M |
| Ending cash balance | 5.18B | 6.47B | 5.63B | 5.23B | 9.39B | 6.57B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | 185.81 | 80.52 | 72.15 | 34.91 | 61.94 | 15,221.82 |
| ROA %i | 8.69 | 10.56 | 3.80 | 7.72 | 8.26 | 3.52 | 3.14 | 3.11 |
| ROIC %i | -- | -- | 7.89 | 14.21 | 15.73 | 8.16 | 8.34 | 8.72 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | 87.06 | 3,094.27 |
| EBIT margin %i | 19.98 | 30.69 | 12.78 | 27.43 | 27.06 | 15.60 | 11.58 | 15.52 |
| FCF / sales %i | 39.05 | 38.39 | 36.66 | 39.13 | 41.77 | 40.62 | 31.65 | 29.13 |
| Current ratioi | 0.98 | 3.18 | 0.84 | 0.79 | 0.96 | 0.87 | 0.66 | 0.67 |
| Quick ratioi | 0.78 | 2.91 | 0.60 | 0.56 | 0.69 | 0.63 | 0.43 | 0.41 |
| Debt / assetsi | 67.92 | 74.88 | 57.16 | 52.33 | 45.58 | 44.08 | 49.68 | 50.39 |
| LT debt / equityi | -- | -- | 593.10 | 416.60 | 342.73 | 503.80 | 1,814.74 | -- |
| Interest coveragei | 4.86 | 5.72 | 2.38 | 6.36 | 7.04 | 3.81 | 2.32 | 3.28 |
| Revenue CAGR (3Y) %i | 12.74 | 9.07 | 17.53 | 19.72 | 20.40 | 5.85 | 0.08 | 1.75 |
| Net income CAGR (3Y) %i | 3.40 | 9.81 | -4.56 | 26.61 | 14.51 | 1.75 | -28.17 | -29.06 |
| FCF CAGR (3Y) %i | 22.23 | 24.86 | 21.20 | 19.80 | 23.82 | 9.53 | -6.75 | -9.76 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 88.15 | 112.90 | 138.53 | 15,221.82 | -- | -- |
| ROA %i | 2.92 | 2.67 | 1.69 | 3.11 | 2.64 | 4.61 |
| ROIC %i | 7.69 | 7.57 | 5.96 | 8.72 | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 11.28 | 10.10 | 7.61 | 15.52 | 14.14 | 18.04 |
| FCF / sales %i | 26.82 | 31.27 | 33.00 | 29.13 | 31.81 | 28.28 |
| Current ratioi | 0.76 | 0.74 | 0.72 | 0.67 | 0.80 | 0.81 |
| Quick ratioi | 0.48 | 0.48 | 0.47 | 0.41 | 0.52 | 0.49 |
| Debt / assetsi | 51.33 | 51.38 | 51.34 | 50.39 | 53.39 | 52.42 |
| LT debt / equityi | 4,544.15 | -- | -- | -- | -- | -- |
| Interest coveragei | 2.27 | 2.06 | 1.58 | 3.28 | 3.05 | 3.98 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- SKYRIZI is the largest reported line at 32.40% of revenue, across 10 reported segments.
- No single line clears half of revenue; Other is next at 17.37%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
SKYRIZI32.40%
Other17.37%
RINVOQ14.86%
All other6.53%
Vraylar6.30%
Botox Therapeutic6.13%
VENCLEXTA4.54%
HUMIRA4.45%
Botox Cosmetic4.28%
IMBRUVICA3.13%
Quote time 2026-10-20 11:00:11 · For reference only, not investment advice and not tailored to your situation.
patent cliff fears priced in years ago and the new drugs stepped up more than skeptics expected. dividend yield here is still doing a lot of the work for the stock.